LON:ABZA

Abzena Competitors

Add

Compare

Today's Range N/A

50-Day Range

15.75

MA: GBX 15.75▼

15.75

52-Week Range N/A

Volume100 shs

Average Volume220,500 shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Abzena (LON:ABZA) Vs. GNS, ABC, BTG, PRTC, OXB, and ERGO

Should you be buying ABZA stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Abzena, including Genus (GNS), Abcam (ABC), BTG (BTG), PureTech Health (PRTC), Oxford Biomedica (OXB), and Ergomed (ERGO).

Abzena vs. Genus Stock

Abzena (LON:ABZA) and Genus (LON:GNS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Abzena and Genus' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abzena	N/A	N/A	N/A	N/A	N/A
Genus	£566.40 million	5.94	N/A	GBX 73.60	69.97

Analyst Ratings

This is a breakdown of recent ratings and target prices for Abzena and Genus, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abzena	0	0	0	0	N/A
Genus	0	1	1	0	2.50

Genus has a consensus price target of GBX 4,760, suggesting a potential downside of 7.57%.

Profitability

This table compares Abzena and Genus' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abzena	N/A	N/A	N/A
Genus	N/A	N/A	N/A

Summary

Genus beats Abzena on 2 of the 2 factors compared between the two stocks.

Abzena vs. Abcam Stock

Abzena (LON:ABZA) and Abcam (LON:ABC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Abzena and Abcam's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abzena	N/A	N/A	N/A	N/A	N/A
Abcam	£269.30 million	12.14	N/A	GBX (0.90)	-1,602.22

Analyst Ratings

This is a breakdown of recent ratings and target prices for Abzena and Abcam, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abzena	0	0	0	0	N/A
Abcam	0	5	1	0	2.17

Abcam has a consensus price target of GBX 1,378.33, suggesting a potential downside of 4.42%.

Profitability

This table compares Abzena and Abcam's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abzena	N/A	N/A	N/A
Abcam	N/A	N/A	N/A

Summary

Abcam beats Abzena on 2 of the 2 factors compared between the two stocks.

Abzena vs. BTG Stock

Abzena (LON:ABZA) and BTG (LON:BTG) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Abzena and BTG's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abzena	N/A	N/A	N/A	N/A	N/A
BTG	£914.10 million	3.57	N/A	GBX 28.50	29.47

Analyst Ratings

This is a breakdown of recent ratings and target prices for Abzena and BTG, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abzena	0	0	0	0	N/A
BTG	0	0	0	0	N/A

Profitability

This table compares Abzena and BTG's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abzena	N/A	N/A	N/A
BTG	N/A	N/A	N/A

Summary

BTG beats Abzena on 1 of the 1 factors compared between the two stocks.

Abzena vs. PureTech Health Stock

Abzena (LON:ABZA) and PureTech Health (LON:PRTC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Abzena and PureTech Health, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abzena	0	0	0	0	N/A
PureTech Health	0	0	4	0	3.00

PureTech Health has a consensus price target of GBX 481.25, suggesting a potential upside of 15.69%.

Profitability

This table compares Abzena and PureTech Health's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abzena	N/A	N/A	N/A
PureTech Health	N/A	N/A	N/A

Earnings and Valuation

This table compares Abzena and PureTech Health's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abzena	N/A	N/A	N/A	N/A	N/A
PureTech Health	£12.26 million	96.98	N/A	GBX 115.50	3.60

Summary

PureTech Health beats Abzena on 2 of the 2 factors compared between the two stocks.

Abzena vs. Oxford Biomedica Stock

Oxford Biomedica (LON:OXB) and Abzena (LON:ABZA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Oxford Biomedica and Abzena, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0	1	2	0	2.67
Abzena	0	0	0	0	N/A

Oxford Biomedica currently has a consensus target price of GBX 926.67, suggesting a potential downside of 7.89%.

Profitability

This table compares Oxford Biomedica and Abzena's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	N/A	N/A	N/A
Abzena	N/A	N/A	N/A

Earnings & Valuation

This table compares Oxford Biomedica and Abzena's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£65.94 million	12.57	N/A	GBX (16.40)	-61.34
Abzena	N/A	N/A	N/A	N/A	N/A

Summary

Oxford Biomedica beats Abzena on 2 of the 2 factors compared between the two stocks.

Abzena vs. Ergomed Stock

Ergomed (LON:ERGO) and Abzena (LON:ABZA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Ergomed and Abzena, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ergomed	0	0	0	0	N/A
Abzena	0	0	0	0	N/A

Profitability

This table compares Ergomed and Abzena's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ergomed	N/A	N/A	N/A
Abzena	N/A	N/A	N/A

Earnings & Valuation

This table compares Ergomed and Abzena's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ergomed	£86.39 million	6.18	N/A	GBX 19.20	57.03
Abzena	N/A	N/A	N/A	N/A	N/A

Summary

Ergomed beats Abzena on 1 of the 1 factors compared between the two stocks.